Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Minatani, Naoko ^a   Waraya, Mina ^a   Yamashita, Keishi ^a   Kikuchi, Mariko ^a   Ushiku, Hideki ^a   Kojo, Ken ^a   Ema, Akira ^a   Nishimiya, Hiroshi ^c   Kosaka, Yoshimasa ^a   Katoh, Hiroshi ^a   Sengoku, Norihiko ^a   Tanino, Hirokazu ^a   Sidransky, David ^b   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Yamato Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE DIOXYGENASE; CYSTEINE DIOXYGENASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG; CYSTEINE DIOXYGENASE, TYPE I, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CDO1 GENE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; FEMALE; GENE; GENE SILENCING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROMOTER REGION; QUANTITATIVE METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; AGED; BREAST NEOPLASMS; DNA SEQUENCE; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CYSTEINE DIOXYGENASE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 84958213516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144862     Document Type: Article

References (33)

1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747. doi: 10.1093/annonc/mdr304 PMID: 21709140
2. Perou CM, Sorlie T, Eisen MB, van de Rijn, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752. PMID: 10963602
3. Sueta A, Ito H, Kawase T, Hirose K, Hosono S, Yatabe Y et al. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat 2012; 132: 711-721. doi: 10.1007/s10549-011-1904-5 PMID: 22160591
4. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009; 45 Suppl 1: 27-40. doi: 10.1016/S0959-8049(09)70013-9 PMID: 19775602
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-1728. PMID: 17387718
6. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167. doi: 10.1200/JCO.2008. 18.1370 PMID: 19204204
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692. PMID: 17320506
8. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-213. PMID: 2423876
9. Gopalakrishnan S, Van Emburgh BO, Robertson KD. DNA methylation in development and human disease. Mutat Res 2008; 647: 30-38. doi: 10.1016/j.mrfmmm.2008.08.006 PMID: 18778722
10. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev 2006; 20: 3215-3231. PMID: 17158741
11. Stefansson OA, Moran S, Gomez A, Sayols C, Arribas Jorba C, Sandoval J et al. A DNA methylationbased definition of biologically distinct breast cancer subtypes. Mol Oncol 2014.
12. Brait M, Ling S, Nagpal JK, Chang X, Park HL, Lee J et al. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One 2012; 7: e44951. doi: 10.1371/journal.pone.0044951 PMID: 23028699
13. Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, Osada M et al. N-methyl-D-Aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 2006; 66: 3409-3418. PMID: 16585162
14. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2: 485-495. PMID: 12498717
15. Yamashita K, Waraya M, Kim MS, Sidransky D, Katada N, Sato T et al. Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study. PLoS One 2014; 9: e113546. doi: 10.1371/journal.pone. 0113546 PMID: 25469504
16. Friedrich K, Weber T, Scheithauer J, Meyer W, Haroske G, Kunze KD et al. Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations. Cell Oncol 2008; 30: 39-50. PMID: 18219109
17. Stipanuk MH, Ueki I, Dominy JE Jr., Simmons CR, Hirschberger LL et al. Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. Amino Acids 2009; 37: 55-63. doi: 10.1007/s00726-008-0202-y PMID: 19011731
18. Oien DB, Moskovitz J. Ablation of the mammalian methionine sulfoxide reductase A affects the expression level of cysteine deoxygenase. Biochem Biophys Res Commun 2007; 352: 556-559. PMID: 17126812
19. Joseph CA, Maroney MJ. Cysteine dioxygenase: structure and mechanism. Chem Commun (Camb) 2007; 3338-3349.
20. Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999; 27: 922-935. PMID: 10569625
21. Jeschke J, O'Hagan HM, Zhang W, Vatapalli R, Calmon MF, Danilova L et al. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. Clin Cancer Res 2013; 19: 3201-3211. doi: 10.1158/1078-0432.CCR-12-3751 PMID: 23630167
22. Ueo H, Shinden Y, Tobo T, Gamachi A, Udo M, Komatsu H et al. Rapid intraoperative visualization of breast lesions with gamma-glutamyl hydroxymethyl rhodamine green. Sci Rep 2015; 5: 12080 doi: 10. 1038/srep12080 PMID: 26165706
23. Kataoka A, Sadanaga N, Mimori K, Ueo H, Barnard GF, Suqimachi K et al. Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis. Clin Cancer Res 2001; 7: 2815-2820 PMID: 11555598
24. Nishimiya H, Kosaka Y, Yamashita K, Minatani N, Kikuchi M, Ema A et al. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up. Anticancer Res 2014; 34: 259-268. PMID: 24403472
25. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312. PMID: 9721092
26. Prabhu A, Sarcar B, Kahali S, Yuan Z, Johnson JJ, Adam KP et al. Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Res 2014; 74: 787-796. doi: 10.1158/0008-5472.CAN-13-1423 PMID: 24351290
27. Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J,Harbeck N et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph nodepositive breast cancer patients. BMC Cancer 2010; 10: 247. doi: 10.1186/1471-2407-10-247 PMID: 20515469
28. McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 2012; 72: 5812-5823. doi: 10.1158/0008-5472.CAN-12-1098 PMID: 23139210
29. Sotgia F, Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Lisanti MP. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res 2011; 13: 213. doi: 10.1186/bcr2892 PMID: 21867571
30. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveauz P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2: 49. doi: 10.3389/fphar.2011. 00049 PMID: 21904528
31. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400. doi: 10.1016/j.ccr.2011.01.038 PMID: 21397861
32. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013; 24: 450-465. doi: 10.1016/j.ccr.2013.08.020 PMID: 24094812
33. Wang F, Yang Y. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat 2014; 147: 203-210. doi: 10.1007/s10549-014-3068-6 PMID: 25085754